The Siberian Scientific Medical Journal
 
 
№ 6 / 2014 / 27-36

Long-term results of therapy by dasatinib and features analysis of the pleural effusion course in patients at late chronic phase of chronic myeloid leukemia after imatinib treatment failure

Author Affiliations

Abstract

The use of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) extends the disease treatment options and allows increasing the frequency of deep stable molecular responses obtaintment in comparison with the therapy by the first generation tyrosine kinase inhibitors. On the other hand, blocking tyrosine kinases can lead to the development of adverse events which decrease the patients’ quality of life. This study presents an experience of treatment of recurrent pleural effusions in the group of  patients in chronic phase CML with long disease history who received dasatinib after prolonged pretreatment and with the development of resistance to imatinib. Also the analyze of the effectiveness of therapeutic methods used in the treatment of pleural effusion has been presented.

Key words

dasatinib, imatinib, tyrosine kinase inhibitors, nilotinib, pleural effusion, recurrent pleural effusions, chronic phase, chronic myeloid leukemia
References
About Authors (Correspondence):

Gusarova G.A. – candidate of medical sciences, senior researcher of the scientific advisory department for chemotherapy myeloproliferative disorders, e-mail: galina1966@bk.ru

Turkina A.G. – doctor of medical sciences, professor, head of the scientific advisory department for chemotherapy myeloproliferative disorders, e-mail: turkianna@yandex.ru

Vorontsova A.V. – candidate of medical sciences, haematologist, e-mail: voroncova9@mail.ru

Goryacheva S.R. – candidate of medical sciences, doctor-hematologist of the scientific advisory department for chemotherapy day hospital, e-mail: svgor@blood.ru

Kuznetsov S.V. – hospital day care haematologist, e-mail: yozhik1966@gmail.com

Chelysheva E.Yu. – candidate of medical sciences, senior researcher of the scientific advisory department for chemotherapy myeloproliferative disorders, e-mail: denve@bk.ru

Lazareva O.V. – candidate of medical sciences, researcher of the scientific advisory department of chemotherapy of mieloproliferative diseases, e-mail: stakhino@gmail.com

Ivanova T.V. – head of medical admission unit

Shukhov O.A. – postgraduate student of the scientific advisory department of chemotherapy of mieloproliferative diseases, e-mail: shuhov@list.ru

Bykova A.V. – postgraduate student of the scientific advisory department for chemotherapy myeloproliferative disorders, e-mail: ivlutaya@mail.ru

Abdullaev A.O. – senior researcher in laboratory of molecular genetics, e-mail: adham_abdullaev@mail.ru

Vinogradova O.Yu. – doctor of medical sciences, chief researcher, е-mail: olgavinz.ru

Full Text

Received: 07/02/2015